title: [GLP-1 agonists: an overview].
abstract: GLP-1 agonists have been widely used in the therapy of type 2 diabetes due to their beneficial effects regarding weight loss and low risk of hypoglycemia. However, some safety concerns have been raised in view of possible detrimental effects to the pancreas. The future place of GLP-1 agonist in diabetes therapy will be determined by the current safety evaluation and data from studies investigating long-term effects.
authors.forename: Iris
authors.initials: I
authors.lastname: Hinneburg
mesh_terms: D001794:Blood Pressure / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010182:Pancreatic Diseases / Q000139:chemically induced / Q000473:pathology; D010455:Peptides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014688:Venoms / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide